66 related articles for article (PubMed ID: 10546069)
1. Review of the molecular modelling studies of the cytochrome P-450 estrogen synthetase enzyme, aromatase.
Ahmed S
Drug Des Discov; 1998 Oct; 15(4):239-52. PubMed ID: 10546069
[TBL] [Abstract][Full Text] [Related]
2. Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme.
Ahmed S; Davis PJ; Owen CP
Drug Des Discov; 1996 Oct; 14(2):91-102. PubMed ID: 9010616
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biochemical evaluation of novel inhibitors of aromatase (AR) using an enhanced representation of the active site of AR derived from the consideration of the reaction mechanism.
Ahmed S; Amanuel Y
Biochem Biophys Res Commun; 2000 Jan; 267(1):356-61. PubMed ID: 10623624
[TBL] [Abstract][Full Text] [Related]
4. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase.
Chen S; Kao YC; Laughton CA
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):107-15. PubMed ID: 9365179
[TBL] [Abstract][Full Text] [Related]
5. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study.
Kao YC; Cam LL; Laughton CA; Zhou D; Chen S
Cancer Res; 1996 Aug; 56(15):3451-60. PubMed ID: 8758911
[TBL] [Abstract][Full Text] [Related]
6. Molecular modelling study of pyrrolidine-2,5-dione based aromatase inhibitors and other known inhibitors.
Ahmed S
Drug Des Discov; 1996 Mar; 14(1):77-89. PubMed ID: 8854046
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibition and inactivation.
Brodie A; Long B
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4343s-4349s; discussion 4411s-4412s. PubMed ID: 11916223
[TBL] [Abstract][Full Text] [Related]
8. Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.
Jackson T; Woo LW; Trusselle MN; Chander SK; Purohit A; Reed MJ; Potter BV
Org Biomol Chem; 2007 Sep; 5(18):2940-52. PubMed ID: 17728860
[TBL] [Abstract][Full Text] [Related]
9. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
Gobbi S; Cavalli A; Rampa A; Belluti F; Piazzi L; Paluszcak A; Hartmann RW; Recanatini M; Bisi A
J Med Chem; 2006 Jul; 49(15):4777-80. PubMed ID: 16854084
[TBL] [Abstract][Full Text] [Related]
10. Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.
Neves MA; Dinis TC; Colombo G; Sá e Melo ML
ChemMedChem; 2007 Dec; 2(12):1750-62. PubMed ID: 17910019
[TBL] [Abstract][Full Text] [Related]
11. Novel oxazolidinone based compounds as inhibitors of aromatase and the use of the substrate-heme complex approach in the rationalisation of these compounds.
Ahmed S; Adat S; Murrells A; Owen CP
Biochem Biophys Res Commun; 2002 Jun; 294(2):380-3. PubMed ID: 12051723
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase.
Hong Y; Cho M; Yuan YC; Chen S
Biochem Pharmacol; 2008 Mar; 75(5):1161-9. PubMed ID: 18184606
[TBL] [Abstract][Full Text] [Related]
13. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.
Lewis DF; Ito Y
Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones.
Kim YW; Hackett JC; Brueggemeier RW
J Med Chem; 2004 Jul; 47(16):4032-40. PubMed ID: 15267241
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional model of CYP19 aromatase for structure-based drug design.
Karkola S; Höltje HD; Wähälä K
J Steroid Biochem Mol Biol; 2007; 105(1-5):63-70. PubMed ID: 17583493
[TBL] [Abstract][Full Text] [Related]
16. The use of the substrate-heme complex approach in the design, synthesis, biochemical evaluation, and rationalization of the inhibitory activity of a range of azole compounds against cholesterol side chain cleavage enzyme.
Ahmed S
Biochem Biophys Res Commun; 2000 Aug; 275(1):75-6. PubMed ID: 10944444
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors.
Cepa MM; Tavares da Silva EJ; Correia-da-Silva G; Roleira FM; Teixeira NA
Steroids; 2008 Dec; 73(14):1409-15. PubMed ID: 18691607
[TBL] [Abstract][Full Text] [Related]
18. How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms.
Lüdemann SK; Lounnas V; Wade RC
J Mol Biol; 2000 Nov; 303(5):797-811. PubMed ID: 11061976
[TBL] [Abstract][Full Text] [Related]
19. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: a molecular modelling study.
Karkola S; Wähälä K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):235-44. PubMed ID: 19000737
[TBL] [Abstract][Full Text] [Related]
20. Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling.
Jackson T; Woo LW; Trusselle MN; Purohit A; Reed MJ; Potter BV
ChemMedChem; 2008 Apr; 3(4):603-18. PubMed ID: 18236493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
